Precigen announces first patient dosed for prgn-2012 adenoverse™ immunotherapy in patients with recurrent respiratory papillomatosis (rrp)

Germantown, md., march 23, 2021 /prnewswire/ -- precigen, inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the phase i study of prgn-2012, a first-in-class, investigational off-the-shelf (ots) adenoverse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (rrp) (clinical trial identifier: nct04724980).
PGEN Ratings Summary
PGEN Quant Ranking